About

Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors.

Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies.

The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.

Technology + Pipeline

Our LOCOcyteTM allogeneic cell-based immunotherapy platform enables potent localized modulation of the immune system which also precipitates a systemic immune response, allowing us to treat previously intractable cancers.

Clinical Trial

NCT05538624

A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary

Brief Summary:
This is an open-label, First-in-Human, Phase 1/2, multicenter study to evaluate the safety and efficacy of a single dose of AVB-001. AVB-001 is an encapsulated cell product engineered to produce native human interleukin-2 (hIL-2). It is delivered intraperitoneally (IP) to patients with high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.

Leadership

Michael Heffernan

Michael Heffernan
Founder & Chief Executive Officer

Michael Heffernan is a successful biopharmaceutical entrepreneur with over 30 years of experience in building and leading development stage and commercial companies. He is a co-founder and CEO of Avenge Bio, Inc. He is also the Founder and Chairman of Collegium Pharmaceutical (COLL), that is focused on developing and commercializing products for the treatment of pain and related disorders. He served as Collegium’s President and CEO from company’s inception until June 2018.

Mr. Heffernan is an advisor, investor and board member in numerous public and private biotech companies. Mr. Heffernan has also held previous positions as CEO of Onset Dermatologics, a commercial stage dermatology company that he founded and spun out of Collegium to create PreCision Dermatology (acquired by Valeant). He was co-founder and CEO of Clinical Studies Ltd., a pharmaceutical contract research organization (acquired by PhyMatrix Corp). Mr. Heffernan began his career at Eli Lilly and Company and served in numerous sales and marketing roles.

Mr. Heffernan was named E&Y Entrepreneur of the Year, Northeast Regional Winner in 2016. He is a registered pharmacist and earned his B.S. Degree in Pharmacy from the University of Connecticut.

Doug Carlson

Doug Carlson
Chief Operating and Financial Officer

Doug Carlson brings over 20 years of experience with a multi-disciplinary background in corporate finance, venture capital, M&A, business development and commercial operations with both large and emerging growth healthcare companies.

Most recently he was the Chief Operating Officer, Chief Financial Officer and Chief Compliance Officer of Ikena Oncology, Inc. (NASDAQ: IKNA). At Ikena, he raised over $260M in private and public capital, led the company’s Initial Public Offering (IPO) in March 2021, and built a robust infrastructure to hire and integrate over 50 new employees.

Mr. Carlson previously worked at Collegium Pharmaceutical (NASDAQ: COLL) and held numerous roles as Vice President, Commercial Operations and Vice President Corporate Strategy & Business Development from 2013 to 2019. At Collegium, he was a member of the management team that led its transformation from a private, clinical stage company with approximately 15 employees to a publicly traded, commercial business with over 300 employees.

Prior to joining Collegium, Mr. Carlson was Senior Director of Business Development at BTG International, Inc. (LSE: BTG) where he was responsible for global specialty pharmaceutical M&A and licensing. Prior to BTG, Mr. Carlson was Senior Director and Head of U.S. Business Development for Lundbeck A/S (LUN: Copenhagen). Mr. Carlson was Director of Corporate Development and M&A at Ovation Pharmaceuticals, Inc., where he played an integral role in the sale of Ovation to Lundbeck in 2009. Prior to Ovation, Mr. Carlson was an Associate in the healthcare group at Pequot Ventures, the venture capital arm of Pequot Capital Management, Inc. Mr. Carlson started his career in the healthcare investing banking group of Cowen & Co. He holds a Bachelor of Arts degree from Trinity College in Hartford, Conn.

Claudio Dansky Ullmann

Claudio Dansky Ullmann
Chief Medical Officer

Claudio Dansky Ullmann, M.D., brings more than 30 years of experience in early and late-stage oncology therapeutics drug development, both solid tumors and hematologic malignancies, in pharmaceutical, biotechnology, government, and academic settings. As a member of executive leadership teams, he oversaw clinical development, operations, and regulatory activities, and helped shape corporate strategy, directly involved in business development activities as well as investor and analyst interactions. Dr. Dansky Ullmann was most recently the Chief Medical Officer at MaxCyte, responsible for the development of CARMA™ cell therapy program. Previously, he was the Senior Vice President, Head of Clinical Development at Infinity Pharmaceuticals, where he led the development of Copiktra until FDA approval, and of eganelisib through first in human studies. Earlier, he was Senior Medical Director, Global Clinical Lead in the Oncology Therapy Area Unit at Takeda Pharmaceuticals. Before, Dr. Dansky Ullmann worked at the Cancer Therapy Evaluation Program, National Cancer Institute, as a Senior Investigator involved in the strategic development of novel agents and therapeutic modalities, including numerous phase 1-3 clinical trials. He was also involved in the development of immunotherapies at Biomira, Inc. and held research fellowship positions in tumor immunotherapy and drug resistance at the NCI. Dr. Dansky Ullmann is a native of Argentina and earned his M.D. at the School of Medicine, Universidad de Buenos Aires. He completed his medical oncology training at Guemes Private Hospital, Buenos Aires.

Manish Jain

Manish Jain
Senior Vice President of Technical Operations

Manish Jain has more than twenty years of experience ranging from small biotech to well established global biopharma demonstrating leadership in CMC development, technical operations, and supply chain of early phase to commercial biopharmaceuticals.

Most recently, Manish was the Vice President of Pharmaceutical Sciences and Manufacturing at Genocea, where he led Process Development, Analytical Development, External Manufacturing, and Supply Chain functions for the portfolio of neoantigen based personalized T-cell therapy and cancer vaccine. Prior to Genocea, Manish worked at several small and big biotechs including Momenta Pharmaceuticals, ImmunoGen, Amgen, and Human Genome Sciences in a variety of technical leadership roles developing multiple clinical and commercial drug products. Manish has expertise in early phase as well as late phase process and analytical development, technology transfer, scale up and scale out, manufacturing operations, and supply chain of biopharmaceuticals.

Manish holds a B. Tech. in Chemical Engineering from the Indian Institute of Technology, Bombay and an M.S. in Chemical Engineering from the University of Virginia.

Karen Andreas

Karen Andreas
VP of Clinical Operations

Karen Andreas is Vice President, Clinical Operations, at Avenge Bio where she is responsible for the oversight of clinical trial activities, clinical operations strategy, planning, and reporting. Her career in biotech spans more than 17 years with cross-functional roles in clinical operations, program management, and quality assurance. She has maintained a primary focus in oncology throughout her industry career at small to mid-size biotech companies including Boston Pharmaceuticals, Merrimack Pharmaceuticals, and ArQule.

Karen is a graduate of Colby College where she majored in Biology. She later earned an MS in the Development and Regulation of Medicines and Devices at Tufts University School of Medicine and is an MBA candidate in Health Sector Management at Boston University’s Questrom School of Business.

Ryan Newman

Ryan Newman
VP of Operations

As VP of Operations at Avenge Bio, Inc., Ryan Newman is responsible for leading cross-functional teams to drive the development of IND-enabling programs, including lead candidate AVB-001. Prior to joining Avenge Bio, Inc. in 2020, Ryan held a number of roles across Business Development and Project Management with a focus in oncology and cell therapy. Most recently, Ryan was responsible for operational management and organization of novel cell therapy programs at Sigilon Therapeutics where he led integrated project teams to deliver on key milestones from proof of concept program data through regulatory submissions and approvals (US and ex-US). Ryan is a graduate of the University of North Carolina at Chapel Hill, where he majored in Biology with a minor in Chemistry. He went on to earn a M.B.A. with a focus in Project Management from the Keller School of Management.

Michael Heffernan

Michael Heffernan
Founder & Chief Executive Officer

Michael Heffernan is a successful biopharmaceutical entrepreneur with over 30 years of experience in building and leading development stage and commercial companies. He is a co-founder and CEO of Avenge Bio, Inc. He is also the Founder and Chairman of Collegium Pharmaceutical (COLL), that is focused on developing and commercializing products for the treatment of pain and related disorders. He served as Collegium’s President and CEO from company’s inception until June 2018.

Mr. Heffernan is an advisor, investor and board member in numerous public and private biotech companies. Mr. Heffernan has also held previous positions as CEO of Onset Dermatologics, a commercial stage dermatology company that he founded and spun out of Collegium to create PreCision Dermatology (acquired by Valeant). He was co-founder and CEO of Clinical Studies Ltd., a pharmaceutical contract research organization (acquired by PhyMatrix Corp). Mr. Heffernan began his career at Eli Lilly and Company and served in numerous sales and marketing roles.

Mr. Heffernan was named E&Y Entrepreneur of the Year, Northeast Regional Winner in 2016. He is a registered pharmacist and earned his B.S. Degree in Pharmacy from the University of Connecticut.

Scott Morenstein

Scott Morenstein
Director

Scott Morenstein serves as Managing Director of CAM Capital, where he leads healthcare investing. CAM Capital was established in 2012 by Bruce Kovner following his retirement from Caxton Associates, the macro hedge fund he founded and managed from 1983 to 2011. Prior to joining CAM Capital in 2013, Mr. Morenstein served as Managing Director at Valence Life Sciences and before that Principal at Caxton Advantage Venture Partners, which he joined in 2007. Prior to joining Caxton Advantage, Mr. Morenstein served as an investment banking associate and founding member of Seaview Securities. Mr. Morenstein began his career at Lehman Brothers as a healthcare investment banker and equity research analyst. Mr. Morenstein has more than 15 years experience in biopharmaceutical investing, equity research and investment banking. Mr. Morenstein led CAM’s investment in and served as a director of Celator Pharmaceuticals until its acquisition by Jazz Pharmaceuticals in July 2016. He was nominated a director of Synta Pharmaceuticals to advise the company as it explored strategic alternatives ultimately leading to a merger with Madrigal Pharmaceuticals. He served as a member of Gemin X’s board of directors until its acquisition by Cephalon. He currently serves as a director of Molecular Templates (Nasdaq: MTEM).

Paul Wotton, PhD

Paul Wotton, PhD
Founder & Director

Dr. Paul K. Wotton is a co-founder and Director at Avenge Bio, bringing significant experience spanning scientific research, product development and corporate growth gained over a thirty-year career. In addition, he serves as CEO of Obsidian Therapeutics. Dr. Wotton previously served as the Founding President and CEO of Sigilon Therapeutics, Inc. Prior to Sigilon, Dr. Wotton served as President and Chief Executive Officer of Ocata Therapeutics until its acquisition by Astellas Pharma where he was also Co-Chairman of the Office of Integration. In previous roles, he served as President and Chief Executive Officer of Antares Pharma (NASDAQ:ATRS) as well as Chief Executive Officer of Topigen Pharmaceuticals. Dr. Wotton is a named inventor on numerous patents and was the Ernst & Young Entrepreneur of the Year Regional (NJ) Winner Life Sciences in 2014. He currently serves on the Boards of Directors of Vericel Corporation (NASDAQ: VCEL), and Cynata Therapeutics (ASX: CYP) as its Chairman, and previously served on the Board of Veloxis Pharmaceuticals A/S prior to its sale to Asahi Kasei.

Ben Askew, PhD

Ben Askew, PhD
Director

Ben Askew serves as a Partner at the Perceptive Xontogeny Venture Fund where he provides and scientific leadership and guidance for preclinical and clinical-stage companies seeded and incubated at Xontogeny.

Ben contributed to the discovery of a number of approved drugs and several additional candidates currently in late-stage clinical trials as a result of his leadership roles in research and early development at Merck (1990-2000), Amgen (2000-2005), and Merck Serono (2005-2011).  In 2011, Ben joined Third Rock Ventures, as entrepreneur-in-residence where he provided strategic input and scientific leadership for several of Third Rock’s portfolio companies, most notably Sage Therapeutics and Blueprint Medicines.  Ben joined SciFluor Life Sciences in 2013 as Vice President of Research, where he has led the expansion SciFluor’s pipeline and advanced two compounds into clinical development.

Ben’s academic training began at Gannon University, where he graduated cum-laude with Bachelor of Science degrees in chemistry and biology. He went on to the University of Pittsburgh, where he obtained a Ph.D. in Organic Chemistry. Ben serves on Scientific Advisory Boards for several Boston-area companies.

Matthew Young

Matthew Young
Managing Director,
Longitude Capital

Matthew P. Young is a managing director of Longitude Capital. Prior to joining Longitude Capital in 2022, Mr. Young was the chief operating officer and chief financial officer of GRAIL, a developer of blood cancer tests that was acquired by Illumina for $8 billion in 2021. Prior to joining GRAIL in October 2019, Mr. Young served as executive vice president and chief financial officer of Jazz Pharmaceuticals – a role he held since February 2015. He served as a senior vice president and the chief financial officer of Jazz beginning in 2014 after working as the senior vice president of corporate development of Jazz since joining the company in 2013. Prior to joining Jazz, Mr. Young worked in investment banking for approximately 20 years, most recently as a managing director in global healthcare of Barclays Capital Inc., an investment banking firm, where his role included acting as the co-head of life sciences at Barclays Capital. From 2007 to 2008, Mr. Young served as a managing director of Citigroup Global Markets Inc., an investment banking firm, and from 2003 to 2007, as a managing director of Lehman Brothers Inc., an investment banking firm. In 2015, he joined the board of directors of PRA Health Sciences Inc., a contract research company. Mr. Young received a B.S. in economics and an M.B.A. from the Wharton School of the University of Pennsylvania.

David E. Moller, MD

David E. Moller, MD
Scientific Advisor

Dr. David Moller has extensive experience in biopharmaceutical R&D across a range of therapeutic areas and modalities. He currently serves as Chief Scientific Officer at Poxel SA, a clinical stage biotechnology company pursuing novel therapies for rare metabolic diseases. David also led R&D efforts as CSO at Sigilon Therapeutics; this technology employs immune-privileged engineered cell implants for the treatment of chronic diseases – including hemophilia and lysosomal storage diseases.  

David’s past experience includes 20 years leading R&D efforts at Merck and Eli Lilly. While Vice President, Metabolic Disorders at Merck, David’s team discovered and delivered several key additions to the pipeline – including sitagliptin (JanuviaTM). As Vice President Endocrine-Cardiovascular and Clinical Investigation at Lilly, David’s team delivered numerous additions to the pipeline including: dulaglutide (TrulicityTM), novel insulins, dual incretin agonists (tirzepatide), and several Phase II-III molecules targeting musculoskeletal, urologic and cardiorenal disorders. While leading global discovery and develop efforts in these areas, David had additional responsibility for scientific assessments of BD projects and execution of partnerships involving clinical stage programs, preclinical projects and technology platforms. At Eli Lilly, David also served as Vice President, Business Development – in this role, he established and led the Emerging Technology and Innovation team; a Boston based effort focusing on access to early phase external innovation across all disease areas including oncology and novel platforms – plus establishing and leveraging flexible funding models and venture capital partnerships. David has also held additional recent roles including as SAB member at Axcella Health and as strategic advisor to TVM Capital.  

David received a B.S. from Brown University and an M.D. from University of Cincinnati. He completed clinical and research training programs at George Washington University and Harvard. David also served on the Harvard faculty for several years where his laboratory discovered important clues to the molecular pathogenesis of metabolic disorders. David has published more than 130 peer-reviewed papers; his honors include election to the American Society of Clinical Investigation, the Association of American Physicians, and appointment as an adjunct professor at the Karolinska Institute.

Katy Rezvani, MD, PhD

Katy Rezvani, MD, PhD
Scientific Advisor

Katy Rezvani M.D, PhD is the Sally Cooper Murray Chair in Cancer Research, Professor of Medicine, Chief of Section for Cellular Therapy, Director of Translational Research and Director of the GMP Facility at MD Anderson Cancer Center. She also serves as the Executive Director of the Adoptive Cell Therapy Platform at MD Anderson. Her research laboratory focuses on the role of natural killer (NK) cells in mediating immunity against hematologic and solid tumors. The goal of this research is to understand mechanisms of tumor-induced NK cell dysfunction and to develop strategies to genetically engineer NK cells in order to enhance their in vivo anti-tumor activity and persistence. Findings from Dr. Rezvani’s lab have led to the approval and funding of several investigator-initiated clinical trials of NK cell immunotherapy in patients with hematologic malignancies and solid tumors, as well as the first-in-human clinical trial of off-the-shelf CAR-transduced cord blood NK cells in patients with relapsed/refractory lymphoid malignancies. Dr. Rezvani’s work is supported by multiple grants from the National Cancer Institute, the Leukemia and Lymphoma Society, the American Cancer Society, Stand Up to Cancer and the Cancer Prevention & Research Institute of Texas (CPRIT). Dr. Rezvani completed her medical training at University College London, followed by Fellowships of the Royal College of Physicians and the Royal College of Pathologists of the United Kingdom, a Ph.D. in Immunology from Imperial College London and postdoctoral studies at the National Institutes of Health.

Omid Veiseh, PhD

Omid Veiseh, PhD
Founder and Chairman of the Scientific Advisory Board

Dr. Omid Veiseh is a Co-Founder of Avenge Bio and an Assistant Professor and CPRIT Scholar in Cancer Research in the Department of Bioengineering at Rice University. He received a dual Ph.D. in Materials Science & Engineering and Nanotechnology from the University of Washington. Dr. Veiseh completed his postdoctoral research with Prof. Robert Langer and Prof. Daniel Anderson at MIT and Harvard Medical School. Over the course of his career he has authored, or co-authored more than 50 peer-reviewed publications including those in Nature, Nature Biotechnology, Nature Materials, Nature Medicine, and is an inventor on 20 pending or awarded patents, many of which have been licensed for commercialization by 3 separate biotechnology companies. He is Co-Founder of Sigilon Therapeutics. Throughout his career he has received numerous awards and fellowships including: a $2 million CPRIT Scholar In Cancer Research Award from the state of Texas, and was named one of MedTech Boston’s 40 Under 40 Healthcare Innovators for 2017.

Amir Anthony Jazaeri, MD

Amir Anthony Jazaeri, MD
Scientific Advisor

Dr. Jazaeri is a Professor and the Vice Chair for Clinical Research in the Department of Gynecologic Oncology and Reproductive Medicine at the University of Texas MD Anderson Cancer Center.  As the Director for the Gynecologic Cancer Immunotherapy Program, he has helped establish a broad base immune-oncology program for gynecologic cancers that include adoptive cell therapies, intraperitoneal immunotherapies, and translational immunobiology. His other areas of research interest include innovative clinical trial designs and identification of novel immunotherapy targets for gynecologic cancers.

José Oberholzer, MD, MHCM, FACS

José Oberholzer, MD, MHCM, FACS
Scientific Advisor

José Oberholzer, M.D., is a physician-scientist with a long track record in cell therapy. Dr. Oberholzer, brings a wealth of highly valuable cell encapsulation expertise to AvengeBio’s Scientific Advisory Board. He is an endowed Professor of Surgery, Experimental Pathology and Biomedical Engineering, and the director of the Charles O. Strickler Transplant Center at the University of Virginia. Previous to that he was a Professor of Surgery and Bioengineering, and Chief of the Division of Transplantation at the University of Illinois at Chicago (UIC). Dr. Oberholzer graduated from the University of Zurich Medical School in Switzerland and obtained a master’s in health care management from Harvard University. He completed his surgical training at the University of Geneva (Switzerland), as well as at the University of Alberta in Edmonton (Canada), where he completed a fellowship in hepatobiliary and pancreatic surgery and transplantation.

Rahul Anil Sheth, MD

Rahul Anil Sheth, MD
Scientific Advisor

Dr. Rahul Sheth is an Assistant Professor in the Department of Interventional Radiology at MD Anderson. Dr. Sheth received his undergraduate degree in Chemistry and Physics at Harvard University and his MD degree through the Health Sciences and Technology program at Harvard Medical School.  After a medicine internship at the University of Pittsburgh, Dr. Sheth returned to Boston and completed his residency training in diagnostic radiology as well as fellowship training in Interventional Radiology at Massachusetts General Hospital. As a clinician-scientist, Dr. Sheth studies how locoregional therapies can have positive systemic ramifications for cancer patients. His research interests include optical molecular imaging, tumor microenvironmental factors affecting minimally invasive cancer therapies, photothermal ablation, and cancer immunology.

Ulrich von Andrian, MD

Ulrich von Andrian, MD
Scientific Advisor

Mallinckrodt Professor of Immunopathology at Harvard Medical School

Program Leader, Basic Immunology at Ragon Institute of MGH, MIT and Harvard

Director, HMS Center for Immune Imaging

Dr. Ulrich H. von Andrian, “Uli”, received his medical degree from the Ludwig-Maximilians University in Munich, Germany, where he also conducted doctorate research on blood-brain barrier dysfunction following brain injury.  In 1989, he joined the La Jolla Institute for Experimental Medicine and UCSD as a postdoctoral fellow working with Dr. Karl-E. Arfors.  His postdoctoral research involved the development of intravital microscopy techniques that led to the discovery of the multi-step leukocyte adhesion cascade in vivo.  After a second postdoctoral fellowship in the laboratory of Dr. Eugene C. Butcher at Stanford University, Dr. von Andrian joined the Faculty of Harvard Medical School in 1994. He was appointed to his current position in 2006. His scientific research is focused on the regulation and function of immune cells in health and disease. To this end, his laboratory employs intravital microscopy techniques combined with other experimental approaches to study the migration, communication, differentiation and function of immune cells in living animals.

Nathan Reticker-Flynn

Nathan Reticker-Flynn
Scientific Advisor

Nathan Reticker-Flynn is a Biomedical Engineer and tumor immunologist working at the interfaces of cancer metastasis, tumor evolution, adaptive immunity, and immuno-oncology. He received his PhD from the Massachusetts Institute of Technology while working with Dr. Sangeeta Bhatia as part of the Harvard-MIT Division of Health Sciences and Technology. His doctoral studies focused upon developing technologies for interrogating interactions between tumors and extracellular matrix during metastatic progression. Dr. Reticker-Flynn performed his postdoctoral studies in the laboratory of Dr. Edgar Engleman at Stanford University School of Medicine. There, his work has focused on using systems approaches and mouse models to investigate tumor-immune interactions during metastasis and responses to immunotherapies. His discoveries include the revelation that effective immunotherapies require systemic activation of anti-tumor immunity and that lymph node metastases serve to reeducate adaptive immune responses in a manner that promotes distant metastasis. He currently focuses on using systems approaches and mouse models to elucidate the mechanisms of tumor-immune tolerance during metastatic progression and to develop novel immunotherapies to treat patients with metastatic disease.

Oct 19, 2022

‘Drug factory’ implants eliminate mesothelioma tumors in mice

Learn More

Apr 7, 2022

Implanted “Drug Factories” Deliver Cancer Treatment Directly to Tumors – National Cancer Institute

Learn More

Nov 17, 2022

Avenge Bio to Present at the Piper Sandler 34th Annual Healthcare Conference

Learn More

Oct 19, 2022

Avenge Bio to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Learn More

Aug 22, 2022

Avenge Bio Announces Peer-Reviewed Publication on Preclinical Proof-of-Concept for LOCOcyte™ Platform Technology in Malignant Mesothelioma

Learn More

Aug 3, 2022

Avenge Bio Announces FDA Clearance of the AVB-001 IND for the Treatment of Ovarian Cancer, a Novel Cellular Therapy Leveraging the LOCOcyte™ Immunotherapy Platform

Learn More

May 20, 2022

Avenge Bio Presents Preclinical Data at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Learn More

Mar 28, 2022

Avenge Bio Appoints Claudio Dansky Ullmann, M.D., as Chief Medical Officer

Learn More

Mar 2, 2022

Avenge Bio Announces Peer-Reviewed Publication on Preclinical Proof of Concept for LOCOcyte™ Platform Technology

Learn More

Feb 22, 2022

Avenge Bio Appoints Douglas Carlson as Chief Operating and Financial Officer

Learn More

Jan 5, 2022

Avenge Bio Announces Closing of $45 Million Series A Financing

Learn More

Nov 11, 2022

Favorable Preclinical Efficacy and Safety Profile of AVB-001 a Novel IL-2 Cell-based Immunotherapy that Eradicates Ovarian Cancer in Mouse Tumor Models and Supports First in Human Clinical Development

Learn More

Nov 10, 2022

IL-12-Based Cytokine Factories Modulate Tumor Microenvironment to Eradicate Pancreatic Tumors in Mice and are Well Tolerated in Non-human Primates

Learn More

Nov 10, 2022

Localized interleukin-2 cytokine factories eradicate mesothelioma tumors via activation of adaptive and innate immune cells

Learn More

Oct 3, 2022

A (Controlled) Spill of IL-2 for Localized Treatment of Mesothelioma

Learn More

Sep 12, 2022

Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors

Learn More

May 4, 2022

Evaluation of Implantable Cytokine Factories for Eradication of Malignant Pleural Mesothelioma (MPM) Tumors in Mice with Safe and Predictable Dosing in Non-human Primates

Learn More

May 4, 2022

IL-12-Based Cytokine Factories Modulate Tumor Microenvironment to Eradicate Pancreatic Tumors in Mice and are Well Tolerated in Non-human Primates

Learn More

Mar 3, 2022

Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors

Learn More

Dec 1, 2021

Tumor Adjacent Cytokine Factories for Eradication of Ovarian Cancer Tumor Burden in Mice Through Cytotoxic T-cell Activation with Safe and Predictable Dosing in Non-human Primates

Learn More

Investors

WANT TO WORK AT AVENGE BIO?careers